BCSH/BSBMT Guidelines for the diagnosis and management of acute graft-versus-host disease

This guideline, written by a joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Bone Marrow Transplantation (BSBMT), reviews the available literature and makes recommendations for the diagnosis and management of acute graft-versus-host disease.

Related conditions

Treatment recommendations for patients with Waldenström’s Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM. Dimopoulos M et al. Blood. 2014 Jul 15. pii: blood-2014-03-565135. [Epub ahead of print]. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Weinhold N et al. Leukemia. 2014 Jul 3. doi: 10.1038/leu.2014.208. [Epub ahead of…

Details

General

European Perspective on Multiple Myeloma Treatment Strategies in 2014. Ludwig H et al. Oncologist. 2014 Jul 25. pii: theoncologist.2014-0042. [Epub ahead of print]. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. Joks M et al. Eur J Haematol. 2014 Jul 10. doi: 10.1111/ejh.12412.…

Details

Biology and genetics

Proteasome function is required for platelet production. Shi DS et al. J Clin Invest. 2014 Jul 25. pii: 75247. doi: 10.1172/JCI75247. [Epub ahead of print]. Overexpression of CYR61/CCN1 in the multiple myeloma microenvironment is associated with superior survival and prevention of bone disease. Johnson SK et al. Blood. 2014 Jul 24. pii: blood-2014-02-555813. [Epub ahead…

Details

Complications of myeloma and its treatments

A Rare Concurrence: Nonischemic Cardiomyopathy and Multiple Myeloma Without Amyloidosis. Gupta T et al. Am J Med. 2014 Jul 21. pii: S0002-9343(14)00592-0. doi: 10.1016/j.amjmed.2014.07.012. [Epub ahead of print]. Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients. Fillatre P et al. Am J Med. 2014 Jul 21. pii: S0002-9343(14)00590-7. doi: 10.1016/j.amjmed.2014.07.010. [Epub…

Details

Current treatments

Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials. Huang H et al. Leuk Res. 2014 Jun 30. pii: S0145-2126(14)00188-X. doi: 10.1016/j.leukres.2014.06.009. [Epub ahead of print]. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple…

Details